Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Milmed Pharmabiotics

Reference number
Coordinator Milmed Unico AB
Funding from Vinnova SEK 11 500
Project duration March 2023 - March 2023
Status Completed
Venture 2023-00007-en

Important results from the project

** Denna text är maskinöversatt ** The goal was to get in touch with companies for the funding of planned clinical studies. We have seven companies that we are discussing further with, so with this our objective with the participation at Swissnordicbio is fulfilled.

Expected long term effects

** Denna text är maskinöversatt ** We are satisfied with the outcome of SwissNordicBio as several meetings resulted in continued dialogue after the conference. Another five representatives from companies that we have sought meetings with want more information from us for a possible continued dialogue.

Approach and implementation

** Denna text är maskinöversatt ** The layout of the conference itself was good. Our own layout was to analyze all the companies and assess which ones were most interesting and suitable for us. We then sought meetings with these selected companies. Unfortunately, some did not respond to the meeting request, which meant that you were blocked from searching for several meetings. When some responded and said no to our request, we immediately sent a request to the next company on our internal priority list.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 14 April 2023

Reference number 2023-00300